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was low. Further, the result needs to be veriﬁed by other
laboratory diagnosis methods in case of Pott’s disease.
OL-039 Can Mycobacterium tuberculosis DNA be
detected in plasma/serum samples from
tuberculosis patients?
D. Chen1 *, B. Gu1, S.Y. Pan1, H. Wang1, Z.H. Yan1,
C. Zhao1, G.Y. Liu1. 1Department of Laboratory Medicine,
the First Afﬁliated Hospital of Nanjing Medical University,
China
Background: Tests based on PCR have shown promise for the
detection of M. tuberculosis in different clinical samples
except plasma/serum. The purpose of this study was to
know that whether M. tuberculosis DNA can be detected in
plasma/serum samples.
Methods: 43 serums and 94 plasma were collected
from 124 clinical diagnosed TB patients. Four different
M. tuberculosis DNA extraction methods, including phenol-
chloroform method, Qiagen kit, Omega kit and magnetic
bead method were compared to get higher sensitivity. One
quantitative ﬂuorescent PCR designed by this study was
used for the detection of M. tuberculosis DNA.
Results: The highest DNA extraction efﬁciency (52.8%)
and the best reproducibility (CV = 26.7%) were seen in
the magnetic bead method. And M. tuberculosis DNA can
really be detected in some samples, and 39 of the 124
(31.5%) TB patients showed M. tuberculosis DNA positive in
plasma/serum samples. Interestingly, 35.3% (12/34) smear
negative cases demonstrate M. tuberculosis DNA positive.
Conclusion: In conclusion, this is the ﬁrst study to
report the existence of circulating M. tuberculosis DNA in
plasma/serum from tuberculosis patients and showed that
the detection of M. tuberculosis DNA may provide valuable
information for the diagnosis of AFB negative TB patients.
OL-040 Rapid identiﬁcation and molecular
characterization of drug resistant
Mycobacterium tuberculosis isolates circulating
in China by multilocus PCR and electrospray
ionization mass spectrometry
F.F. Wang1 *, D.J. Ecker2, W.H. Zhang1, Y.-W. Tang3.
1Department of Infectious Diseases, Huashan Hospital,
Fudan University, Shanghai, China, 2Ibis Biosciences,
Inc., a subsidiary of Abbott Molecular, Inc., Carlsbad,
CA, 2Departments of Pathology and Medicine, Vanderbilt
University Medical Center, Nashville, TN, USA
Objective: The emergence of multidrug-resistant (MDR)-TB
and more recently, of extensively drug-resistant (XDR)-TB is
a real threat to achieve TB control and elimination. Quick
detection of drug resistance is an urgent clinical need for
personalized treatment to control MDR-TB or XDR-TB.
Methods: We used multilocus PCR and electrospray
ionization mass spectrometry (PCR/ESI-MS) to determine the
genotype and drug resistance proﬁles for 96 Mycobacterium
tuberculosis isolates circulating in low and high endemic
regions (Shanghai, n = 49; Chongqing, n = 47) in China.
Results: The mutation proﬁles obtained by the PCR/ESI-MS
assay indicated that Principal Genetic Group 1 (PGG1) proﬁle
(87.5%) was dominant across the isolates tested in China.
The results revealed that a cluster of 11 isolates with katG
S315T & inhA promoter C-15T, rpoB S531L, and embB M306I
in Chongqing, the high TB endemic region, which was not
observed in Shanghai, the low endemic region. In addition,
another resistance mutation proﬁle with katG S315T & inhA
promoter T-8C, rpoB D516G & P564R/A, was detected in
10 isolates in high endemic region in comparison to one
in low endemic region. Drug-resistant gene mutations were
more diversiﬁed in the low endemic region than in the high
endemic region.
Conclusion: PCR/ESI-MS can provide another rapid and
accurate laboratory diagnostic tool for antituberculosis drug
resistance determination. This new technique has potential
to facilitate rapid determination of MDR-TB in China,
allowing timely guidance for individualized treatment.
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PL-006 HBV infection modeling and numerical
simulation for anti-HBV infection personalized
combination therapy
X. Chen1, L.Q. Min1 *, Y.A. Ye2, Q. Zhang1. 1University
of Science and Technology Beijing, 2Traditional Chinese
Internal Medicine Key Laboratory of China Education
Ministry, Dongzhimen Hospital, Beijing University of
Chinese Medicine, China
Background: Some chronic HBV (CHB) patients have normal
ALTs and hepatic injuries. Chinese herbal medicine and
nucleosides combination treatments may be effective for
some of such kind patients. It needs to develop an anti-HBV
infection treatment model to interpret the mechanism for
curable CHB patients with near normal liver functions.
Methods: A 57 years old male chronic HBeAg positive patient
(nucleosides-native) received Chinese Herbal Medicine (CHM
15 23 ingredients, 450 600 g) treatment two times daily
for 24 weeks, switched to CHM + Adefovir Dipivoxil for
53 weeks, then switched to CHM + Entecavir for 21 weeks.
A new differential equation model is introduced to describe
the dynamics of anti-HBV infection treatment, in which
a term is in charge of killing virus rather than infected
hepatocytes.
Results: His HBeAg got seroconversion at week 98. The
numerical simulation of the model and his HBV DNA, ALT
are shown in following ﬁgure.
Conclusions: Analysis shows that a treated CHB patient
with infective number R0 < 1 will eventually be cured. Large
value of that term makes patient’s virus be eventually
cleared without damaging hepatocytes.
Acknowledgment: This work is supported by the 11 5 Key
Special Project of China (No. 2008ZX10005 006).
OL-041 Evaluation of serum level changes of
sCD26 & sCD30 before and after treatment
with interferon among naive chronic hepatitis B
patients
M. Alavi-Moghaddam1 *. 1Shahid Beheshti University Of
Medical Sciences, Iran
Propose: To evaluate the role of serum levels of sCD26
and sCD30 in predicting the outcome of therapy with IFNa
among naïve chronic hepatitis B patients.
